CA-DATAPLOR
dataplor, the leading provider of global location intelligence, today announced a $10.6 million Series A funding round led by Spark Capital. This round, which included participation from Quest Venture Partners, Acronym Venture Capital, Circadian Ventures, Two Lanterns Venture Partners and APA Venture Partners, will further accelerate dataplor’s ongoing expansion, building the most accurate, comprehensive and dynamically updated database of global Point of Interest (POI) data on the market.
Today, dataplor offers data coverage across more than 200 countries and territories, encompassing over 300 million locations and over 15,000 brands. Companies in industries including technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance rely on dataplor’s global, accurate coverage to power strategic decisions and investments. With this latest funding, dataplor is positioned to expand its worldwide coverage and continue building out its team.
“Our mission at dataplor has always been about unlocking the true potential of POI data, making it accessible and actionable at a global scale,” said Geoff Michener, CEO and founder of dataplor. “This funding validates our vision and market-leading product and empowers us to accelerate our efforts, driving growth while aligned to our core values of accuracy, quality and privacy.”
dataplor’s proprietary approach merges technologies including artificial intelligence, machine learning, LLMs, and a purpose built technology platform with a global team of expert human validators. This combination allows the company to gather accurate, deduplicated and verified location data while providing a framework for regular updates to the information to stay current.
“dataplor solves a critical gap for companies seeking to scale in international markets: accurate, actionable data that unlocks business opportunities,” said Alex Finkelstein, General Partner at Spark Capital. “We see a massive potential market opportunity ahead for dataplor, but we’ve also been impressed by their traction, winning dozens of Fortune 500 customers and growing revenue by an average of 2.5x year-over-year since 2020. We’re very confident in this company’s bright future.”
Finkelstein will join dataplor’s board of directors, which includes John Frankel, founding partner of ffVC.
In addition to receiving accurate, updated and global POI data coverage, dataplor’s customers also benefit from the company’s commitment to privacy. All of the information in dataplor’s datasets is gathered through direct contact with a business or through publicly available data; no personally identifiable information (PII) is used. This approach not only aligns with the company’s ethical commitments but also ensures dataplor’s customers won’t be burdened with any regulatory or legal repercussions.
About dataplor
dataplor is a leading geospatial data company that helps global enterprises grow abroad by mapping tough-to-reach markets with a privacy-first approach. As the majority of international location data is inaccurate and quickly out of date, dataplor goes several steps further than the industry standard to help the world’s largest companies in technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance understand intelligence about any commercial or physical location in the world, in real-time, to fuel expansion abroad.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418167357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 204023.6.2025 14:00:00 CEST | Press release
Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi). This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes: By 2030: A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy), 100% renewable energy consumption across all Group sites, A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories. By 2040: Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emi
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row23.6.2025 14:00:00 CEST | Press release
Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/ Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.) Euromonitor International is the foremost provider of globa
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries23.6.2025 13:00:00 CEST | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit www.plasmaservicesgroup.com
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression23.6.2025 12:30:00 CEST | Press release
A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo armsOngoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy dataSecond ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom